Information Provided By: 
Fly News Breaks for April 21, 2016
SPPI, LGND
Apr 21, 2016 | 08:45 EDT
Roth Capital analyst Joseph Pantgini remains a buyer of Ligand Pharmaceuticals (LGND) after Spectrum's (SPPI) Evomela received Orphan status by the FDA providing seven years of market exclusivity. The analyst noted that Ligand is entitled to a 20% royalty on Evomela revenue. Pantgini expects that current revenue streams from partnered products and the broad "in development" portfolio will drive "significant" growth in the near and longer term. The analyst reiterates a Buy rating and $147 price target on Ligand's shares.
News For LGND;SPPI From the Last 2 Days
There are no results for your query LGND;SPPI
